SCLX - NASDAQ
Scilex Holding Company
$7.45
+0.54%Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
At a Glance
Live Snapshotsclx
Cash and Short Term Investments
Last Annual Value
10.98M
3-Year CAGR
71%
5-Year CAGR
18%
10-Year CAGR
9%
Scilex Holding Company Competitors Analysis of Cash and Short Term Investments
| Company | Cash and Short Term Investments | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Scilex Holding Company NASDAQ:SCLX | 10.98M | 41.0% | 20.4% | N/A | |
 Alector, Inc. NASDAQ:ALEC | 256.02M | -22.4% | -19.0% | 17.5% | |
 Insight Molecular Diagnostics Inc. NASDAQ:IMDX | 11.58M | 7.1% | -19.3% | -0.7% | |
 aTyr Pharma, Inc. NASDAQ:ATYR | 78.69M | -7.1% | -6.1% | 0.9% | |
 Biomea Fusion, Inc. NASDAQ:BMEA | 55.81M | -31.9% | -20.3% | N/A | |
 MacroGenics, Inc. NASDAQ:MGNX | 189.91M | -6.2% | -4.9% | -4.0% | |
 Metagenomi, Inc. Common Stock NASDAQ:MGX | 160.80M | -16.0% | 8.3% | N/A | |
 Quince Therapeutics, Inc. NASDAQ:QNCX | 40.78M | -18.4% | -17.5% | N/A | |
 Surrozen, Inc. NASDAQ:SRZN | 89.25M | 35.3% | -2.6% | N/A | |
 Zentalis Pharmaceuticals, Inc. NASDAQ:ZNTL | 245.89M | -20.1% | -6.3% | N/A | |
 Agenus Inc. NASDAQ:AGEN | 3.00M | -66.0% | -60.4% | -27.7% |
Scilex Holding Company Fair Value Envelope
Related Guides
Continue your SCLX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.